Schwartz J A, Skafar D F
Department of Physiology, Wayne State University School of Medicine, Detroit, Michigan 48201.
Biochemistry. 1993 Sep 28;32(38):10109-15. doi: 10.1021/bi00089a029.
The studies presented here show how changing the structure of the ligand can affect the conformation of the receptor. Five different estradiol analogs have been tested for binding to the calf uterine estrogen receptor. In three of the analogs the phenolic hydroxyl group had been moved from the 3 to the 1, 2, or 4 position on the A-ring (1-hydroxyestratrien-17 beta-ol, 2-hydroxyestratrien-17 beta-ol, or 4-hydroxyestratrien-17 beta-ol). In the remaining two analogs either the A- or the D-ring hydroxyl group had been removed altogether (estratrien-17 beta-ol or 3-hydroxyestratriene). Competition binding assay showed that the relative binding affinity for the estrogen receptor had been weakened by all changes in the structure of the ligand. Furthermore, the ligands in which either the 3 beta- or the 17 beta-hydroxyl group was missing produced nonparallel slopes in the linear portions of the displacement curves compared to that of estradiol; the ligands in which the phenolic hydroxyl had simply been moved around the A-ring, however, did not. These observations implied that the receptor binding mechanism used by the monohydroxyl ligands was different from that of estradiol. Saturation binding analysis showed that while the presence of any of the dihydroxyl ligands or that of estratrien-17 beta-ol decreased the positive cooperativity of the [3H]estradiol-estrogen receptor interaction, the presence of the 3-hydroxyestratriene ligand increased it. These results suggest that both the binding mechanism and the affinity of the ligand for the receptor are exquisitely sensitive to the structure of the ligand.
